170 related articles for article (PubMed ID: 29975795)
1. Increased risk of all-cause mortality associated with domperidone use in Parkinson's patients: a population-based cohort study in the UK.
Simeonova M; de Vries F; Pouwels S; Driessen JHM; Leufkens HGM; Cadarette SM; Burden AM
Br J Clin Pharmacol; 2018 Nov; 84(11):2551-2561. PubMed ID: 29975795
[TBL] [Abstract][Full Text] [Related]
2. Ventricular tachyarrhythmia and sudden cardiac death with domperidone use in Parkinson's disease.
Renoux C; Dell'Aniello S; Khairy P; Marras C; Bugden S; Turin TC; Blais L; Tamim H; Evans C; Steele R; Dormuth C; Ernst P;
Br J Clin Pharmacol; 2016 Aug; 82(2):461-72. PubMed ID: 27062307
[TBL] [Abstract][Full Text] [Related]
3. The association between domperidone and ventricular arrhythmia in the postpartum period.
Smolina K; Mintzes B; Hanley GE; Oberlander TF; Morgan SG
Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1210-1214. PubMed ID: 27296864
[TBL] [Abstract][Full Text] [Related]
4. Domperidone in Parkinson's disease: a perilous arrhythmogenic or the gold standard?
Lertxundi U; Domingo-Echaburu S; Soraluce A; García M; Ruiz-Osante B; Aguirre C
Curr Drug Saf; 2013 Feb; 8(1):63-8. PubMed ID: 23656449
[TBL] [Abstract][Full Text] [Related]
5. DA-9701 on gastric motility in patients with Parkinson's disease: A randomized controlled trial.
Shin CM; Lee YJ; Kim JM; Lee JY; Kim KJ; Choi YJ; Kim N; Lee DH
Parkinsonism Relat Disord; 2018 Sep; 54():84-89. PubMed ID: 29705555
[TBL] [Abstract][Full Text] [Related]
6. Quantitative study of salivary secretion in Parkinson's disease.
Tumilasci OR; Cersósimo MG; Belforte JE; Micheli FE; Benarroch EE; Pazo JH
Mov Disord; 2006 May; 21(5):660-7. PubMed ID: 16419045
[TBL] [Abstract][Full Text] [Related]
7. Effects of central dopaminergic stimulation by apomorphine on swallowing disorders in Parkinson's disease.
Tison F; Wiart L; Guatterie M; Fouillet N; Lozano V; Henry P; Barat M
Mov Disord; 1996 Nov; 11(6):729-32. PubMed ID: 8914103
[TBL] [Abstract][Full Text] [Related]
8. Domperidone for Hypotension in Parkinson's Disease: A Systematic Review.
Bacchi S; Chim I; Kramer P; Postuma RB
J Parkinsons Dis; 2017; 7(4):603-617. PubMed ID: 29103053
[TBL] [Abstract][Full Text] [Related]
9. Domperidone, cytochrome P450 3A4 isoenzyme inhibitors and ventricular arrhythmia: a nationwide case-crossover study.
Chen HL; Hsiao FY
Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):841-8. PubMed ID: 26098410
[TBL] [Abstract][Full Text] [Related]
10. Domperidone for insufficient lactation in England 2002-2015: A drug utilization study with interrupted time series analysis.
Mehrabadi A; Reynier P; Platt RW; Filion KB
Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1316-1324. PubMed ID: 30106193
[TBL] [Abstract][Full Text] [Related]
11. Domperidone and Parkinson's disease.
Parkes JD
Clin Neuropharmacol; 1986; 9(6):517-32. PubMed ID: 3542205
[No Abstract] [Full Text] [Related]
12. Mortality and quality of death certification in a cohort of patients with Parkinson's disease and matched controls in North Wales, UK at 18 years: a community-based cohort study.
Hobson P; Meara J
BMJ Open; 2018 Feb; 8(2):e018969. PubMed ID: 29444783
[TBL] [Abstract][Full Text] [Related]
13. Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Proton Pump Inhibitors, or Metoclopramide: A Population-Based Nested Case-Control Study.
Arana A; Johannes CB; McQuay LJ; Varas-Lorenzo C; Fife D; Rothman KJ
Drug Saf; 2015 Dec; 38(12):1187-99. PubMed ID: 26350642
[TBL] [Abstract][Full Text] [Related]
14. Restless legs syndrome outside the blood-brain barrier--exacerbation by domperidone in Parkinson's disease.
Rios Romenets S; Dauvilliers Y; Cochen De Cock V; Carlander B; Bayard S; Galatas C; Wolfson C; Postuma RB
Parkinsonism Relat Disord; 2013 Jan; 19(1):92-4. PubMed ID: 22922159
[TBL] [Abstract][Full Text] [Related]
15. Domperidone, Parkinson disease and sudden cardiac death: Mice and men show the way.
Scorza FA; Scorza CA; Ferraz HB
Clinics (Sao Paulo); 2016 Feb; 71(2):59-61. PubMed ID: 26934232
[No Abstract] [Full Text] [Related]
16. Association of Antipsychotic Use With Mortality Risk in Patients With Parkinson Disease.
Weintraub D; Chiang C; Kim HM; Wilkinson J; Marras C; Stanislawski B; Mamikonyan E; Kales HC
JAMA Neurol; 2016 May; 73(5):535-41. PubMed ID: 26999262
[TBL] [Abstract][Full Text] [Related]
17. Quick titration of pergolide in cotreatment with domperidone is safe and effective.
Jansen PA; Herings RM; Samson MM; De Vreede PL; Schuurmans-Daemen LM; Hovestadt A; Verhaar HJ; Van Laar T
Clin Neuropharmacol; 2001; 24(3):177-80. PubMed ID: 11391131
[TBL] [Abstract][Full Text] [Related]
18. Domperidone and ventricular arrhythmia or sudden cardiac death: a population-based case-control study in the Netherlands.
van Noord C; Dieleman JP; van Herpen G; Verhamme K; Sturkenboom MC
Drug Saf; 2010 Nov; 33(11):1003-14. PubMed ID: 20925438
[TBL] [Abstract][Full Text] [Related]
19. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease.
Soykan I; Sarosiek I; Shifflett J; Wooten GF; McCallum RW
Mov Disord; 1997 Nov; 12(6):952-7. PubMed ID: 9399220
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular and mortality risks in Parkinson's disease patients treated with entacapone.
Graham DJ; Williams JR; Hsueh YH; Calia K; Levenson M; Pinheiro SP; Macurdy TE; Shih D; Worrall C; Kelman JA
Mov Disord; 2013 Apr; 28(4):490-7. PubMed ID: 23443994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
